CAD and head and neck squamous cell carcinoma: Based on KEYNOTE-048, the FDA approved use of pembrolizumab monotherapy in the first-line for R/M HNSCC with CPS ≥1 and pembrolizumab plus platinum-based chemotherapy for those with CPS<1 R/M HNSCC (31).